FY2025 EPS Estimates for Codexis Raised by Cantor Fitzgerald

Codexis, Inc. (NASDAQ:CDXS) – Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Codexis in a research note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn ($0.49) per share for the year, up from their previous forecast of ($0.51). Cantor Fitzgerald currently has a “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis Price Performance

Codexis stock opened at $2.73 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis has a 1 year low of $2.47 and a 1 year high of $6.08. The firm has a 50-day moving average of $4.42 and a two-hundred day moving average of $3.96. The stock has a market cap of $226.15 million, a price-to-earnings ratio of -3.14 and a beta of 2.12.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The firm had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%.

Hedge Funds Weigh In On Codexis

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC raised its stake in Codexis by 51.1% in the third quarter. Barclays PLC now owns 207,628 shares of the biotechnology company’s stock valued at $640,000 after buying an additional 70,255 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Codexis by 0.7% in the third quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock valued at $5,065,000 after buying an additional 11,082 shares during the last quarter. State Street Corp grew its holdings in Codexis by 2.7% in the third quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock valued at $4,778,000 after purchasing an additional 41,480 shares during the period. Tallon Kerry Patrick acquired a new position in Codexis during the fourth quarter valued at approximately $2,018,000. Finally, Inspire Investing LLC purchased a new position in Codexis in the 4th quarter worth approximately $405,000. 78.54% of the stock is owned by hedge funds and other institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.